To go back to the main page, click here
| S.No | Drug Name | Biological Name | Developer | Current Development Phase | Additional Information | Start Date | Completion Date | Source |
| 11 | Sunitinib, Cyclophosphamide | IMA901 plus GM-CSF | Immatics Biotechnologies GmbH | III | The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters | 2010 | 2011 | Source |
| 12 | - | PSMA/PRAME | MannKind Corporation | I | Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. |
2007 | 2009 | Source |
| 13 | - | EphA2 Vaccine/ MEDI-543 |
MedImmune | Preclinical | - | - | - | - |
| 14 | - | V934/V935 | Merck | I | Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors. |
2008 | 2011 | Source |
| 15 | - | MGN1601 | Mologen AG | I/II | This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma. | 2010 | 2019 | Source |
| 16 | Interferon-alpha | TroVax® | Oxford BioMedica | II | Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression. | 2006 | 2008 | Source |
| 17 | - | AdhTAP | TapImmune | Preclinical | - | - | - | - |
To go back to the main page, click here